Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
Expert Rev Clin Pharmacol
; 10(5): 559-565, 2017 May.
Article
in En
| MEDLINE
| ID: mdl-28286977
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
Camptothecin
/
Antineoplastic Combined Chemotherapy Protocols
/
Health Care Costs
Type of study:
Health_economic_evaluation
/
Observational_studies
/
Risk_factors_studies
Language:
En
Journal:
Expert Rev Clin Pharmacol
Year:
2017
Type:
Article
Affiliation country:
United States